Total Payments
$34,424
2024 Payments
$4,408
Companies
8
Transactions
52
Medicare Patients
1,152
Medicare Billing
$253,592
Payment Breakdown by Category
Consulting$11,520 (33.5%)
Travel$11,388 (33.1%)
Other$10,040 (29.2%)
Food & Beverage$1,458 (4.2%)
Education$18.09 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,520 | 5 | 33.5% |
| Travel and Lodging | $11,388 | 21 | 33.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,390 | 4 | 24.4% |
| Honoraria | $1,650 | 1 | 4.8% |
| Food and Beverage | $1,458 | 20 | 4.2% |
| Education | $18.09 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $13,044 | 19 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,802 | 1 | $0 (2017) |
| Incyte Corporation | $5,417 | 14 | $0 (2019) |
| Eisai Inc. | $4,751 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $3,463 | 4 | $0 (2024) |
| Eli Lilly and Company | $1,741 | 6 | $0 (2017) |
| Genentech USA, Inc. | $110.78 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $94.70 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,408 | 3 | AstraZeneca Pharmaceuticals LP ($2,740) |
| 2023 | $5,594 | 12 | Exelixis Inc. ($3,218) |
| 2020 | $7,075 | 5 | Exelixis Inc. ($4,455) |
| 2019 | $5,502 | 15 | Incyte Corporation ($5,417) |
| 2018 | $4,225 | 9 | Exelixis Inc. ($3,636) |
| 2017 | $7,620 | 8 | Bayer HealthCare Pharmaceuticals Inc. ($5,802) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,650.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 04/14/2023 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $541.53 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $297.05 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $249.00 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $44.34 | General |
| Category: Oncology | ||||||
| 03/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $40.68 | General |
| Category: Oncology | ||||||
| 02/23/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,935.00 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $110.78 | General |
| 01/20/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $70.95 | General |
| 01/19/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $134.70 | General |
| Category: Oncology | ||||||
| 08/13/2020 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 08/13/2020 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 01/29/2020 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $495.00 | General |
| 01/25/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 01/25/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $120.37 | General |
| Category: Oncology | ||||||
| 10/12/2019 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,880.00 | General |
| 10/12/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| 10/12/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| 10/12/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $47.21 | General |
| 10/12/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $34.84 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 326 | 706 | $386,097 | $77,402 |
| 2022 | 6 | 271 | 572 | $344,186 | $59,174 |
| 2021 | 5 | 253 | 606 | $351,730 | $62,306 |
| 2020 | 6 | 302 | 589 | $227,842 | $54,711 |
Total Patients
1,152
Total Services
2,473
Medicare Billing
$253,592
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 71 | 192 | $116,480 | $24,768 | 21.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 206 | $76,510 | $22,081 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 97 | 197 | $122,160 | $16,915 | 13.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 32 | 32 | $26,450 | $5,222 | 19.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 29 | $21,953 | $4,532 | 20.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 23 | 24 | $7,421 | $1,780 | 24.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $8,184 | $1,319 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $6,939 | $784.34 | 11.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 99 | 256 | $155,932 | $22,644 | 14.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 135 | $95,518 | $17,681 | 18.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 99 | $36,432 | $8,973 | 24.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 47 | 47 | $36,154 | $5,824 | 16.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $11,186 | $2,958 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 18 | $8,964 | $1,093 | 12.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 103 | 292 | $174,304 | $25,734 | 14.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 66 | 176 | $106,956 | $22,863 | 21.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 70 | $25,760 | $6,612 | 25.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 44 | 44 | $34,408 | $5,690 | 16.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 24 | $10,302 | $1,407 | 13.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 74 | 183 | $57,332 | $18,524 | 32.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 99 | 229 | $81,825 | $15,903 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 74 | $27,232 | $7,075 | 26.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 41 | 41 | $25,738 | $4,985 | 19.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 20 | $13,160 | $3,843 | 29.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 22 | 22 | $7,194 | $2,952 | 41.0% |
About Dr. Gregory Heestand, M.D
Dr. Gregory Heestand, M.D is a Medical Oncology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1770568867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Heestand, M.D has received a total of $34,424 in payments from pharmaceutical and medical device companies, with $4,408 received in 2024. These payments were reported across 52 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($11,520).
As a Medicare-enrolled provider, Heestand has provided services to 1,152 Medicare beneficiaries, totaling 2,473 services with total Medicare billing of $253,592. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Stanford, CA
- Active Since 12/12/2005
- Last Updated 05/07/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770568867
Products in Payments
- Cabometyx (Drug) $7,681
- CABOMETYX (Drug) $4,868
- Lenvima (Drug) $4,680
- IMFINZI (Drug) $588.55
- IMFINZI (Biological) $134.70
- KEYTRUDA (Biological) $94.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Stanford
Sandhya Srinivas, Md, MD
Medical Oncology — Payments: $272,187
Medical Oncology $272,187
Ranjana Advani, Md, MD
Medical Oncology — Payments: $184,712
Medical Oncology $184,712
Kristen Ganjoo, Md, MD
Medical Oncology — Payments: $69,790
Medical Oncology $69,790
Heather Wakelee, Md, MD
Medical Oncology — Payments: $52,107
Medical Oncology $52,107
Arash Alizadeh, Md, Phd, MD, PHD
Medical Oncology — Payments: $46,821
Medical Oncology $46,821
Caroline Berube, Md, MD
Medical Oncology — Payments: $30,092
Medical Oncology $30,092